Handa is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $2.1B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Handa's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Cabometyx | Exelixis | Generic | 2031 | Application filed (capsules) | $2.1B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Handa's share of it.